question_id,date,category,question_text,baseline_success,baseline_actually_answered,baseline_has_expected,baseline_confidence,baseline_text,baseline_error,baseline_time,baseline_input_tokens,baseline_output_tokens,togomcp_success,togomcp_has_expected,togomcp_confidence,togomcp_text,togomcp_error,togomcp_time,togomcp_input_tokens,togomcp_output_tokens,togomcp_cache_creation_input_tokens,togomcp_cache_read_input_tokens,tools_used,tool_details,value_add,expected_answer,notes
37,2026-01-31,Structured Query,What FDA-approved drugs act as enzyme inhibitors and what are their protein targets?,True,True,True,0.5333333333333333,"# FDA-Approved Enzyme Inhibitor Drugs and Their Protein Targets

There are hundreds of FDA-approved enzyme inhibitors. Here's a comprehensive overview organized by enzyme class:

## **Kinase Inhibitors**
- **Imatinib (Gleevec)** - BCR-ABL tyrosine kinase, c-KIT, PDGFR
- **Erlotinib (Tarceva)** - EGFR tyrosine kinase
- **Gefitinib (Iressa)** - EGFR tyrosine kinase
- **Sunitinib (Sutent)** - Multiple receptor tyrosine kinases (VEGFR, PDGFR, KIT)
- **Sorafenib (Nexavar)** - RAF kinases, VEGFR, PDGFR
- **Vemurafenib (Zelboraf)** - BRAF V600E kinase
- **Dabrafenib (Tafinlar)** - BRAF kinase
- **Crizotinib (Xalkori)** - ALK, ROS1, MET kinases

## **ACE Inhibitors (Cardiovascular)**
- **Lisinopril, Enalapril, Ramipril, Captopril** - Angiotensin-converting enzyme (ACE)

## **Protease Inhibitors**

### HIV Protease Inhibitors:
- **Ritonavir, Lopinavir, Atazanavir, Darunavir** - HIV-1 protease

### HCV Protease Inhibitors:
- **Simeprevir, Paritaprevir, Grazoprevir** - HCV NS3/4A serine protease

## **HMG-CoA Reductase Inhibitors (Statins)**
- **Atorvastatin, Simvastatin, Rosuvastatin, Pravastatin** - HMG-CoA reductase

## **Proton Pump Inhibitors**
- **Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole** - H+/K+-ATPase (gastric proton pump)

## **Cyclooxygenase (COX) Inhibitors**
- **Aspirin, Ibuprofen, Naproxen** - COX-1 and COX-2
- **Celecoxib (Celebrex)** - Selective COX-2

## **Phosphodiesterase Inhibitors**
- **Sildenafil (Viagra)** - PDE5
- **Tadalafil (Cialis)** - PDE5
- **Roflumilast** - PDE4

## **Monoamine Oxidase Inhibitors (MAOIs)**
- **Selegiline, Rasagiline** - MAO-B (for Parkinson's)
- **Phenelzine, Tranylcypromine** - MAO-A and MAO-B (antidepressants)

## **Acetylcholinesterase Inhibitors**
- **Donepezil, Rivastigmine, Galantamine** - Acetylcholinesterase (for Alzheimer's)

## **Carbonic Anhydrase Inhibitors**
- **Acetazolamide, Dorzolamide** - Carbonic anhydrase

## **Xanthine Oxidase Inhibitors**
- **Allopurinol, Febuxostat** - Xanthine oxidase (for gout)

## **Aromatase Inhibitors**
- **Letrozole, Anastrozole, Exemestane** - Aromatase (CYP19A1)

## **DPP-4 Inhibitors (Diabetes)**
- **Sitagliptin, Saxagliptin, Linagliptin** - Dipeptidyl peptidase-4

## **Neuraminidase Inhibitors**
- **Oseltamivir (Tamiflu), Zanamivir** - Influenza neuraminidase

## **SGLT2 Inhibitors (Diabetes)**
- **Canagliflozin, Dapagliflozin, Empagliflozin** - Sodium-glucose cotransporter 2

## **Integrase Inhibitors (HIV)**
- **Raltegravir, Dolutegravir, Bictegravir** - HIV integrase

This represents a significant portion of FDA-approved enzyme inhibitors, though the complete list contains many more drugs across various therapeutic categories.",,15.521274089813232,54,1137,True,False,0.4666666666666667,"Based on my research using biological databases and PubMed literature, I can provide you with comprehensive information about FDA-approved drugs that act as enzyme inhibitors and their protein targets.

## FDA-Approved Enzyme Inhibitors and Their Protein Targets

### **1. Tyrosine Kinase Inhibitors (TKIs)**

**Drugs:**
- **Imatinib** (ChEMBL941) - Target: BCR-ABL fusion protein (ChEMBL6105), also inhibits c-KIT and PDGFR
- **Gefitinib** (CHEMBL939) - Target: Epidermal Growth Factor Receptor/EGFR (ChEMBL203)
- **Erlotinib** (CHEMBL553) - Target: Epidermal Growth Factor Receptor/EGFR (ChEMBL203)

These are used primarily in cancer treatment, targeting specific kinases involved in cell proliferation and survival.

### **2. JAK Inhibitors**

**Drug:**
- **Upadacitinib** - Target: Janus Kinase 1 (JAK1)
- **Baricitinib** - Target: JAK1/JAK2

According to PubMed research, upadacitinib is a second-generation oral JAK inhibitor that selectively targets JAK1, modulating downstream inflammatory pathways. It received FDA approval in January 2022 for moderate to severe atopic dermatitis. ([DOI: 10.25259/IJDVL_133_2025](https://doi.org/10.25259/IJDVL_133_2025))

### **3. HMG-CoA Reductase Inhibitors (Statins)**

**Drug:**
- **Atorvastatin** (CHEMBL1487) - Target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase (ChEMBL402)

Used to lower cholesterol by inhibiting the rate-limiting enzyme in cholesterol synthesis.

### **4. ACE Inhibitors**

**Drug:**
- **Lisinopril** (CHEMBL419213) - Target: Angiotensin-Converting Enzyme (ChEMBL2096989)

Used to treat hypertension and heart failure by blocking the conversion of angiotensin I to angiotensin II.

### **5. HIV Protease Inhibitors**

**Drug:**
- **Ritonavir** (CHEMBL163) - Target: HIV protease (ChEMBL3638323)

Used in combination therapy for HIV/AIDS treatment by inhibiting viral protease essential for viral replication.

### **6. COX-2 Inhibitors**

**Drug:**
- **Celecoxib** (CHEMBL118) - Target: Cyclooxygenase-2 (COX-2/Prostaglandin G/H synthase 2)
- **Aspirin** (CHEMBL25) - Target: Cyclooxygenase-1 and -2 (COX-1 and COX-2)

Used as anti-inflammatory drugs by inhibiting prostaglandin synthesis.

### **7. Phosphodiesterase Inhibitors**

**Drug:**
- **Sildenafil** (CHEMBL192) - Target: cGMP-specific 3',5'-cyclic phosphodiesterase type 5 (PDE5) (ChEMBL1827)

Used for erectile dysfunction and pulmonary hypertension by inhibiting PDE5.

### **8. Proton Pump Inhibitors**

**Drug:**
- **Omeprazole** (CHEMBL1503) - Target: H+/K+-ATPase (Potassium-transporting ATPase) (ChEMBL2095173)

Used to reduce stomach acid production by inhibiting the proton pump in gastric parietal cells.

### **9. Dihydrofolate Reductase Inhibitors**

**Drug:**
- **Methotrexate** (CHEMBL3244648) - Target: Dihydrofolate reductase (DHFR) (ChEMBL202)

Used in cancer chemotherapy and autoimmune diseases by inhibiting folate metabolism.

### **10. Topoisomerase Inhibitors**

**Drug:**
- **Etoposide** - Target: DNA topoisomerase II

According to PubMed, etoposide is a topoisomerase II inhibitor that induces transient double-strand breaks. Recent research shows it can be enhanced with ATM kinase inhibitors in breast cancer treatment. ([DOI: 10.1371/journal.pone.0340472](https://doi.org/10.1371/journal.pone.0340472))

**Recent FDA Approvals:**
- **Gepotidacin** and **Zoliflodacin** - Target: DNA gyrase and topoisomerase IV (bacterial enzymes)

These represent newly approved antibacterial classes targeting bacterial type II topoisomerases, approved in 2025. ([DOI: 10.3390/ijms27010496](https://doi.org/10.3390/ijms27010496))

### **11. ALDH2 Inhibitors**

**Drug:**
- **Disulfiram** - Target: Aldehyde dehydrogenase 2 (ALDH2)

According to recent PubMed research, SOPH-110S is a novel ALDH2 inhibitor currently in development for alcohol use disorder, with the FDA approving its IND for phase 1 studies in September 2025. ([DOI: 10.3390/cells15020123](https://doi.org/10.3390/cells15020123))

---

**Key Points:**
- Enzyme inhibitors represent one of the largest classes of FDA-approved drugs
- They target various enzyme families including kinases, proteases, reductases, and ATPases
- Many are used in oncology (kinase inhibitors, topoisomerase inhibitors)
- Others treat cardiovascular disease (statins, ACE inhibitors), inflammation (COX inhibitors), and infectious diseases (protease inhibitors)
- The field continues to evolve with new selective inhibitors being developed and approved

**Sources:**
According to PubMed and ChEMBL databases, which provide comprehensive bioactivity and drug target information.",,179.28152799606323,52,4038,15087,259847,"mcp__chembl__search_chembl_molecule, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__run_sparql, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target","[{""name"": ""mcp__chembl__search_chembl_molecule"", ""input"": {""query"": ""FDA approved enzyme inhibitor"", ""limit"": ""20""}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""FDA approved enzyme inhibitors protein targets"", ""max_results"": 10}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41597198"", ""41559918"", ""41557625"", ""41518320"", ""41516368""]}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""imatinib"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""aspirin"", ""limit"": 5}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?drug ?drugName ?target ?targetName ?targetType\nWHERE {\n  ?drug a chembl:SmallMolecule ;\n        rdfs:label ?drugName ;\n        chembl:hasActivity ?activity .\n  \n  ?activity chembl:hasAssay ?assay ;\n            chembl:standardRelation \""=\"" ;\n            chembl:standardType \""IC50\"" .\n  \n  ?assay chembl:hasTarget ?target .\n  \n  ?target rdfs:label ?targetName ;\n          chembl:targetType ?targetType .\n  \n  FILTER(CONTAINS(LCASE(?targetType), \""enzyme\""))\n  FILTER(CONTAINS(LCASE(?drugName), \""inhibit\"") || \n         CONTAINS(LCASE(?drugName), \""ib\"") ||\n         REGEX(?drugName, \""mab$\"", \""i\""))\n}\nLIMIT 50\n""}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""kinase inhibitor FDA approved"", ""limit"": 20}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""protease inhibitor HIV"", ""limit"": 20}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""gefitinib"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""erlotinib"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""atorvastatin"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""lisinopril"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""ritonavir"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""EGFR epidermal growth factor receptor"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""HMG-CoA reductase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""ACE angiotensin converting enzyme"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""HIV protease"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""BCR-ABL tyrosine kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""methotrexate"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""sildenafil"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""omeprazole"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""dihydrofolate reductase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""phosphodiesterase type 5"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""H+/K+ ATPase proton pump"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""COX-2 cyclooxygenase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""PDE5 phosphodiesterase 5"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""celecoxib"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""JAK janus kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""topoisomerase"", ""limit"": 5}}]",VALUABLE,"List of approved inhibitor drugs with their targets, such as SIMVASTATIN (HMG-CoA reductase), ERLOTINIB (EGFR), COLCHICINE (Tubulin)","COMPLEX QUERY requiring DrugMechanism knowledge.

Databases/Resources: ChEMBL

Knowledge Required:
- DrugMechanism entity connects molecule to target with action type
- mechanismActionType = 'INHIBITOR' filter
- highestDevelopmentPhase = 4 for marketed drugs
- Human target filtering via organism

Without proper knowledge: Cannot navigate DrugMechanism model or filter correctly.

Verified in chembl_exploration.md Pattern 5 (Drug Mechanism of Action Analysis)."
38,2026-01-31,Structured Query,What Japanese rare diseases are classified as intractable diseases eligible for government support?,True,True,True,0.5,"In Japan, the government designates certain rare diseases as **""Nanbyo"" (難病)** or intractable diseases that qualify for financial and medical support. As of recent years, there are over 330 designated intractable diseases.

## Key Categories Include:

**Neurological/Neuromuscular:**
- Amyotrophic Lateral Sclerosis (ALS)
- Spinocerebellar degeneration
- Multiple sclerosis
- Myasthenia gravis
- Muscular dystrophies (various types)
- Moyamoya disease

**Autoimmune/Rheumatic:**
- Systemic lupus erythematosus (SLE)
- Systemic sclerosis
- Mixed connective tissue disease
- Behçet's disease
- Dermatomyositis/Polymyositis

**Metabolic/Endocrine:**
- Hypopituitarism
- Primary adrenal insufficiency
- Various mitochondrial diseases

**Hematological:**
- Aplastic anemia
- Idiopathic thrombocytopenic purpura (ITP)

**Pulmonary:**
- Idiopathic pulmonary fibrosis
- Pulmonary arterial hypertension

**Gastrointestinal:**
- Crohn's disease
- Ulcerative colitis

## Eligibility Criteria:
Diseases must meet criteria such as:
- Unknown etiology
- No established treatment
- Chronic course requiring long-term care
- Low prevalence
- Significant impact on daily life

The government provides subsidies for medical expenses and research support for these designated conditions. The list is periodically updated by the Ministry of Health, Labour and Welfare.",,7.950463056564331,53,410,True,True,0.875,"Based on my search of the NANDO (Nanbyo Data) database, I can provide you with comprehensive information about Japanese rare diseases classified as intractable diseases eligible for government support.

## Overview

Japan has **2,454 designated intractable diseases** that are eligible for government support. These diseases are maintained in the NANDO (Nanbyo Data) ontology, which is a comprehensive database managed by the Japanese government.

## Key Characteristics

**Designation System**: Each designated intractable disease has:
- A notification number (告示番号) assigned by the government
- Japanese and English names
- Cross-references to international disease databases like MONDO
- Official documentation from the Ministry of Health, Labour and Welfare (MHLW)

## Sample of Designated Intractable Diseases

Here are some examples organized by notification number:

### Notification Number 1:
- **Spinal and bulbar muscular atrophy** (球脊髄性筋萎縮症)
- **Malignant thymoma** (悪性胸腺腫)
- **Ulcerative colitis** (潰瘍性大腸炎)
- **Type 1 diabetes** (1型糖尿病)
- **Hereditary spherocytosis** (遺伝性球状赤血球症)
- **Angelman syndrome** (アンジェルマン症候群)

### Notification Number 2:
- **Amyotrophic lateral sclerosis (ALS)** (筋萎縮性側索硬化症)
- **Crohn's disease** (クローン病)
- **Sickle cell disease** (鎌状赤血球症)
- **X-linked agammaglobulinemia** (X連鎖無ガンマグロブリン血症)

### Notification Number 3:
- **Spinal muscular atrophy** (脊髄性筋萎縮症) - Types I-IV
- **Osteogenesis imperfecta** (骨形成不全症)
- **Xeroderma pigmentosum** (色素性乾皮症)
- **Canavan disease** (カナバン病)

### Notification Number 4:
- **Takayasu arteritis** (高安動脈炎)
- **Dilated cardiomyopathy** (拡張型心筋症)
- **Stevens-Johnson syndrome** (スティーヴンス・ジョンソン症候群)
- **Toxic epidermal necrolysis** (中毒性表皮壊死症)

## Disease Categories

The intractable diseases span multiple categories including:
- Neuromuscular diseases
- Metabolic diseases
- Cardiovascular diseases
- Immune system disorders
- Blood disorders
- Connective tissue disorders
- Rare cancers
- Congenital disorders

## Government Support

These designated intractable diseases are eligible for special government subsidies and support programs under Japan's Intractable Disease Policy, which provides:
- Medical expense subsidies
- Research funding
- Patient support services
- Clinical care coordination

The complete list is maintained and updated quarterly by the Japanese government, with approximately 88% of all diseases in the NANDO database having official designation status with notification numbers.",,40.96426224708557,21,1487,22408,142447,"mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""nando""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""nando"", ""sparql_query"": ""PREFIX owl: <http://www.w3.org/2002/07/owl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX dct: <http://purl.org/dc/terms/>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\nPREFIX nando: <http://nanbyodata.jp/ontology/NANDO_>\n\nSELECT ?disease ?identifier ?prefLabel ?en_label ?notif_num\nFROM <http://nanbyodata.jp/ontology/nando>\nWHERE {\n  ?disease a owl:Class ;\n           dct:identifier ?identifier ;\n           skos:prefLabel ?prefLabel ;\n           nando:hasNotificationNumber ?notif_num .\n  OPTIONAL {\n    ?disease rdfs:label ?en_label .\n    FILTER(LANG(?en_label) = \""en\"")\n  }\n}\nORDER BY xsd:integer(?notif_num)\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""nando"", ""sparql_query"": ""PREFIX owl: <http://www.w3.org/2002/07/owl#>\nPREFIX dct: <http://purl.org/dc/terms/>\nPREFIX nando: <http://nanbyodata.jp/ontology/NANDO_>\n\nSELECT (COUNT(DISTINCT ?disease) as ?total_count)\nFROM <http://nanbyodata.jp/ontology/nando>\nWHERE {\n  ?disease a owl:Class ;\n           nando:hasNotificationNumber ?notif_num .\n}""}}]",VALUABLE,"List of designated intractable diseases from NANDO including Parkinson's disease, amyotrophic lateral sclerosis, and others with notification numbers","COMPLEX QUERY requiring NANDO structure knowledge.

Databases/Resources: NANDO

Knowledge Required:
- Multilingual label handling (English, Japanese kanji, hiragana)
- Notification number for designated diseases
- bif:contains with boolean operators for keyword search
- Cross-reference to MONDO via skos:closeMatch (84% coverage)

Without proper knowledge: Cannot navigate multilingual labels or find cross-database mappings.

Verified in nando_exploration.md Pattern 1 (Multilingual Disease Search)."
39,2026-01-31,Integration,What biological processes are associated with human enzymes that catalyze phosphate transfer reactions?,True,True,False,0.45454545454545453,"Enzymes that catalyze phosphate transfer reactions (primarily **kinases** and **phosphatases**) are involved in numerous critical biological processes:

## Signal Transduction
- Protein phosphorylation/dephosphorylation cascades
- Cell surface receptor signaling (receptor tyrosine kinases, serine/threonine kinases)
- Second messenger pathways (cAMP, calcium signaling)

## Cell Cycle Regulation
- Cell division control via cyclin-dependent kinases (CDKs)
- Checkpoint regulation
- Mitotic spindle formation

## Metabolism and Energy
- ATP synthesis/hydrolysis
- Glycolysis (hexokinase, phosphofructokinase, pyruvate kinase)
- Gluconeogenesis
- Glycogen metabolism (glycogen phosphorylase, glycogen synthase)
- Fatty acid metabolism
- Krebs cycle regulation

## Gene Expression
- Transcription factor activation/inactivation
- RNA polymerase regulation
- Chromatin remodeling

## Apoptosis
- Programmed cell death pathways
- Caspase regulation

## Cell Growth and Differentiation
- Growth factor signaling
- Developmental pathways
- Stem cell differentiation

## DNA Replication and Repair
- Nucleotide synthesis (nucleoside kinases)
- DNA damage response
- Cell cycle checkpoints

## Immune Response
- T-cell and B-cell activation
- Cytokine signaling
- Inflammatory responses

## Muscle Contraction
- Myosin light chain phosphorylation
- Calcium signaling

These phosphorylation events serve as molecular ""switches"" that regulate protein activity, localization, and interactions throughout the cell.",,10.107070922851562,55,405,True,True,0.6363636363636364,"Based on my search of biological databases, I can provide you with comprehensive information about the biological processes associated with human enzymes that catalyze phosphate transfer reactions.

## Overview

Human enzymes that catalyze phosphate transfer reactions are primarily **kinases** and **phosphotransferases**. These enzymes transfer phosphate groups (typically from ATP) to target molecules, a process called **phosphorylation**.

## Major Types of Human Phosphotransferases

From the UniProt database, human phosphotransferases include:

1. **Protein Kinases** - Transfer phosphate to proteins
   - Serine/threonine kinases (e.g., CDKs, PKA, AMPK)
   - Tyrosine kinases (e.g., receptor tyrosine kinases like EGFR, FLT3)
   - Dual-specificity kinases

2. **Small Molecule Kinases**
   - Adenosine kinase
   - Glycerol kinase
   - Riboflavin kinase
   - Adenylate kinase

## Key Biological Processes

Based on Gene Ontology (GO) annotations, these enzymes are involved in:

### 1. **Cell Cycle Regulation**
- Cyclin-dependent kinases (CDK1, CDK2, CDK5, CDK6, CDK7, CDK9) control cell division
- Regulate progression through G1, S, G2, and M phases

### 2. **Signal Transduction**
- Receptor tyrosine kinases (RTKs) transmit signals from outside to inside cells
- MAPK (mitogen-activated protein kinase) cascades
- PI3K/AKT signaling pathway
- cAMP-dependent protein kinase (PKA) signaling

### 3. **Metabolic Regulation**
- AMP-activated protein kinase (AMPK) - energy homeostasis sensor
- Regulates glucose and lipid metabolism
- Phosphorylation of metabolic enzymes controls their activity

### 4. **Gene Expression and Transcription**
- Phosphorylation of transcription factors (e.g., STAT proteins, JUN)
- RNA polymerase II phosphorylation by CDK7
- Chromatin remodeling

### 5. **Immune Response**
- Interferon-induced protein kinase (PKR)
- NF-κB pathway activation via I-κB phosphorylation
- STAT protein phosphorylation in cytokine signaling

### 6. **DNA Damage Response**
- DNA-dependent protein kinase activity
- Cell cycle checkpoint control
- DNA repair pathways

### 7. **Cellular Stress Response**
- Protein phosphorylation in response to stress
- Autophagy regulation (ULK1 kinase complex)
- Apoptosis regulation

### 8. **Development and Differentiation**
- Control of cell fate decisions
- Tissue-specific gene expression
- Morphogenesis

### 9. **Synaptic Transmission and Neuronal Function**
- Tau protein phosphorylation (important in Alzheimer's disease)
- Synaptic plasticity
- Neurotransmitter receptor modulation

### 10. **Protein Quality Control**
- Targeting proteins for degradation via phosphorylation
- Regulation of protein-protein interactions
- Control of protein localization

## Molecular Functions

These enzymes exhibit:
- **Kinase activity** (GO:0016301)
- **Phosphotransferase activity** (GO:0016772)
- **Protein kinase activity** (GO:0004672)
- **Transferase activity, transferring phosphorus-containing groups**

## Clinical Significance

Many of these enzymes are targets for therapeutic intervention:
- Cancer therapy (kinase inhibitors like imatinib for chronic myeloid leukemia)
- Inflammatory diseases
- Metabolic disorders
- Neurodegenerative diseases

The phosphorylation reactions catalyzed by these enzymes represent one of the most important post-translational modifications in biology, serving as molecular switches that control virtually every aspect of cellular function.",,44.850374937057495,17,1678,45136,112589,"mcp__togomcp__search_uniprot_entity, mcp__ols__searchClasses, mcp__ols__searchClasses, mcp__ols__searchClasses, mcp__ols__fetch, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""human kinase phosphotransferase"", ""limit"": 20}}, {""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""phosphate transfer reaction"", ""pageSize"": 20}}, {""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""phosphorylation biological process"", ""pageSize"": 20}}, {""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""protein kinase activity"", ""ontologyId"": ""go"", ""pageSize"": 10}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0006468""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\n\nSELECT DISTINCT ?goterm ?label\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:classifiedWith ?goterm .\n  ?goterm rdfs:label ?label .\n  FILTER(CONTAINS(LCASE(?label), \""kinase\"") || CONTAINS(LCASE(?label), \""phosphotransferase\""))\n  FILTER(STRSTARTS(STR(?goterm), \""http://purl.obolibrary.org/obo/GO\""))\n}\nLIMIT 50""}}]",CRITICAL,"GO biological processes associated with phosphate-transfer enzymes, such as pentose-phosphate shunt, signal transduction","COMPLEX QUERY requiring three-way integration.

Databases/Resources: UniProt, Rhea, GO

Knowledge Required:
- Three GRAPH blocks required (Rhea, UniProt, GO)
- GO term filtering via STRSTARTS
- up:reviewed 1 and rhea:status filters essential
- bif:contains for 'phosphate' search in equations

Without proper knowledge: Three-way join fails or times out without proper filtering.

Verified in rhea_exploration.md Pattern 4 (Three-Way Join)."
40,2026-01-31,Integration,What genes and their protein products are annotated in the DDBJ nucleotide sequence database for E. coli?,True,False,True,0.5833333333333334,"I don't have access to specific, current DDBJ (DNA Data Bank of Japan) database entries or their real-time contents. However, I can tell you about the general types of genes and protein products that would typically be annotated for *E. coli* in nucleotide sequence databases like DDBJ:

## Common E. coli Gene Categories:

**Metabolic genes:**
- *lac* operon genes (lacZ, lacY, lacA) - lactose metabolism
- *trp* operon genes - tryptophan biosynthesis
- Glycolysis and TCA cycle enzymes

**Replication and transcription:**
- *dnaA, dnaB, dnaC* - DNA replication initiation
- *polA, polB, polC* - DNA polymerases
- RNA polymerase subunits (*rpoA, rpoB, rpoC, rpoD*)

**Translation machinery:**
- Ribosomal proteins (rpl, rps genes)
- tRNA genes
- Aminoacyl-tRNA synthetases

**Cell structure:**
- Cell wall biosynthesis genes
- Outer membrane proteins
- Flagellar genes (*fli, flg, flh*)

**Regulation:**
- *crp* (cAMP receptor protein)
- Sigma factors
- Two-component regulatory systems

The complete *E. coli* K-12 genome contains approximately **4,300 protein-coding genes**. For specific, current annotations in DDBJ, you would need to query their database directly at their website or through their API.

Would you like information about any specific category of *E. coli* genes?",,8.968547821044922,63,389,True,True,0.75,"Perfect! Now let me compile a comprehensive summary of genes and their protein products for E. coli. Based on the data I've gathered from multiple sources (NCBI Gene database and UniProt), here's what I found:

## **Genes and Protein Products Annotated for E. coli (K-12 strain MG1655)**

### **Overview**
The DDBJ (DNA Data Bank of Japan) nucleotide sequence database contains comprehensive annotations for *Escherichia coli*, particularly the well-studied K-12 strain. There are **over 26,000 genes** annotated for E. coli K-12, including protein-coding genes, ribosomal RNAs, transfer RNAs, and non-coding RNAs.

### **Key Protein-Coding Genes and Their Products:**

#### **1. DNA Replication and Repair**
- **recA** (Gene ID: 947170)
  - **Protein**: DNA recombination/repair protein RecA (UniProt: P0A7G6)
  - **Function**: DNA recombination and repair; essential for homologous recombination
  - **Location**: Chromosome positions 2,822,707-2,823,768

- **dnaA** (Gene ID: 948217)
  - **Protein**: Chromosomal replication initiator protein DnaA (UniProt: P03004)
  - **Function**: Initiates chromosomal replication; binds to origin of replication
  - **Location**: Chromosome positions 3,882,325-3,883,728

#### **2. Cell Division**
- **ftsZ** (Gene ID: 944786)
  - **Protein**: Cell division protein FtsZ (UniProt: P0A9A6)
  - **Function**: Forms Z-ring at division site; essential for bacterial cell division
  - **Location**: Chromosome positions 105,304-106,455

#### **3. Transcription Machinery**
- **rpoD** (Gene ID: 947567)
  - **Protein**: RNA polymerase sigma factor RpoD (Sigma-70)
  - **Function**: Primary sigma factor during exponential growth; directs RNA polymerase to promoters
  - **Location**: Chromosome positions 3,213,046-3,214,887

- **rpoB** (Gene ID: 948488)
  - **Protein**: RNA polymerase subunit beta
  - **Function**: Core subunit of RNA polymerase; involved in RNA synthesis
  - **Location**: Chromosome positions 4,181,244-4,185,272

- **rpoS** (Gene ID: 947210)
  - **Protein**: RNA polymerase sigma factor RpoS (Sigma-38)
  - **Function**: Master regulator of general stress response
  - **Location**: Chromosome positions 2,866,558-2,867,550

- **rho** (Gene ID: 948297)
  - **Protein**: Transcription termination factor Rho
  - **Function**: Required for transcription termination
  - **Location**: Chromosome positions 3,966,416-3,967,675

#### **4. Protein Folding and Quality Control**
- **dnaK** (Gene ID: 944750)
  - **Protein**: Chaperone protein DnaK (Hsp70 family)
  - **Function**: ATP-regulated binding and release of polypeptide substrates; prevents protein aggregation
  - **Location**: Chromosome positions 12,162-14,078

#### **5. Protein Translocation**
- **secA** (Gene ID: 944821)
  - **Protein**: Protein translocation ATPase
  - **Function**: Component of Sec protein secretion system; translocates proteins across inner membrane
  - **Location**: Chromosome positions 108,278-110,983

#### **6. Transcriptional Regulation**
- **crp** (Gene ID: 947867)
  - **Protein**: DNA-binding transcriptional dual regulator CRP (cAMP receptor protein)
  - **Function**: Global transcriptional regulator; responds to cAMP levels
  - **Location**: Chromosome positions 3,486,119-3,486,751

- **hns** (Gene ID: 945829)
  - **Protein**: DNA-binding transcriptional dual regulator H-NS
  - **Function**: Nucleoid-associated protein; transcriptional repressor of horizontally acquired genes
  - **Location**: Chromosome positions 1,292,508-1,292,921

#### **7. Metabolic Enzymes**
- **lacZ** (Gene ID: 945006)
  - **Protein**: Beta-galactosidase (UniProt: P00722)
  - **Function**: Cleaves lactose into glucose and galactose
  - **Location**: Chromosome positions 363,230-366,304

### **RNA Genes (Non-protein coding):**

#### **Ribosomal RNAs:**
- **16S rRNA genes**: rrsB, rrsC, rrsD, rrsE, rrsG, rrsH (multiple copies)
  - **Function**: Component of 30S ribosomal subunit; essential for protein synthesis
  
- **23S rRNA genes**: rrlB and others
  - **Function**: Component of 50S ribosomal subunit; catalyzes peptide bond formation

#### **Non-coding RNAs:**
- **rnpB** (Gene ID: 947634)
  - **Product**: RNase P RNA component class A
  - **Function**: Ribozyme involved in tRNA processing

### **Database Cross-References:**

The DDBJ annotations include extensive cross-references to:
- **NCBI Protein**: For protein sequence information
- **NCBI Taxonomy** (taxid: 511145): For organism classification
- **UniProt/Swiss-Prot**: For reviewed protein annotations
- **BioProject and BioSample**: For experimental context

### **Annotation Features:**

Each gene entry in DDBJ typically includes:
1. **Locus tag** (e.g., b2699 for recA)
2. **Gene symbol** (e.g., recA, lacZ)
3. **Product description** (protein name)
4. **Genomic coordinates** (using FALDO ontology)
5. **Protein translation** (amino acid sequence)
6. **Codon start position**
7. **Translation table** (typically table 11 for bacteria)
8. **Cross-references to protein databases**

This represents just a small sample of the extensive genomic annotations available for E. coli in the DDBJ database. The complete genome contains thousands of protein-coding genes involved in all aspects of bacterial physiology, metabolism, and regulation.",,114.54471206665039,63,3999,23830,475898,"mcp__togomcp__get_MIE_file, mcp__togomcp__get_sparql_endpoints, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary, mcp__togomcp__ncbi_esearch, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__ncbi_esummary, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity","[{""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""ddbj""}}, {""name"": ""mcp__togomcp__get_sparql_endpoints"", ""input"": {}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""ddbj"", ""sparql_query"": ""PREFIX nuc: <http://ddbj.nig.ac.jp/ontologies/nucleotide/>\nPREFIX sio: <http://semanticscience.org/resource/>\n\nSELECT DISTINCT ?entry_id ?organism\nFROM <http://rdfportal.org/dataset/ddbj>\nWHERE {\n  ?entry a nuc:Entry ;\n         dcterms:identifier ?entry_id ;\n         nuc:organism ?organism .\n  ?organism bif:contains \""'escherichia' AND 'coli'\"" option (score ?relevance) .\n}\nORDER BY DESC(?relevance)\nLIMIT 5""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""ddbj"", ""sparql_query"": ""PREFIX nuc: <http://ddbj.nig.ac.jp/ontologies/nucleotide/>\nPREFIX dcterms: <http://purl.org/dc/terms/>\n\nSELECT DISTINCT ?entry_id ?organism\nFROM <http://rdfportal.org/dataset/ddbj>\nWHERE {\n  ?entry a nuc:Entry ;\n         dcterms:identifier ?entry_id ;\n         nuc:organism ?organism .\n  FILTER(REGEX(?organism, \""Escherichia coli\"", \""i\""))\n}\nLIMIT 5""}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""Escherichia coli[organism] AND complete genome[title]"", ""max_results"": 10}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""Escherichia coli K-12[organism]"", ""max_results"": 20}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""gene"", ""ids"": [""947170"", ""948466"", ""948217"", ""947777"", ""948511"", ""947071"", ""944897"", ""948270"", ""947867"", ""947634""]}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""Escherichia coli K-12[organism] AND protein_coding[gene type]"", ""max_results"": 20}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""organism:\""Escherichia coli K-12\"" AND reviewed:true"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""Escherichia coli K12 recA"", ""limit"": 5}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""gene"", ""ids"": [""944786"", ""947567"", ""944750"", ""948488"", ""947210"", ""948297"", ""948473"", ""945829"", ""945006"", ""944821""]}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\n\nSELECT ?protein ?proteinName ?geneName ?function\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:511145 ;\n           up:recommendedName ?recName ;\n           up:encodedBy ?gene .\n  ?recName up:fullName ?proteinName .\n  ?gene skos:prefLabel ?geneName .\n  OPTIONAL { ?protein up:function/rdfs:comment ?function }\n  FILTER(?geneName IN (\""recA\"", \""dnaA\"", \""ftsZ\"", \""rpoD\"", \""dnaK\"", \""lacZ\""))\n}\nLIMIT 10""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT ?protein ?proteinName ?geneName ?sequence\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:511145 ;\n           up:reviewed true ;\n           up:recommendedName ?recName ;\n           up:encodedBy ?gene ;\n           up:sequence ?seq .\n  ?recName up:fullName ?proteinName .\n  ?gene skos:prefLabel ?geneName .\n  ?seq rdf:value ?sequence .\n  FILTER(?geneName IN (\""recA\"", \""dnaA\"", \""ftsZ\"", \""rpoD\"", \""dnaK\""))\n}\nLIMIT 5""}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""Escherichia coli K12 dnaA"", ""limit"": 3}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""Escherichia coli K12 ftsZ"", ""limit"": 3}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""Escherichia coli K12 lacZ"", ""limit"": 3}}]",CRITICAL,E. coli genes with CDS and protein annotations from DDBJ including various enzymes and structural proteins,"COMPLEX QUERY requiring DDBJ structure knowledge.

Databases/Resources: DDBJ, NCBI Taxonomy

Knowledge Required:
- Entry-level filtering CRITICAL (262M entries without filter = timeout)
- Gene-CDS-Protein relationship via sio:SIO_010081
- Organism filtering via ro:0002162 to NCBI Taxonomy
- FILTER(CONTAINS(STR(?feature), 'ACCESSION')) pattern essential

Without proper knowledge: Query times out processing entire 262M entry dataset.

Verified in ddbj_exploration.md Pattern 1 (Entry-level Filtering)."
41,2026-01-31,Completeness,How many pathogenic variants are recorded in ClinVar?,True,False,True,0.5,"I don't have access to real-time data about the current number of pathogenic variants in ClinVar, as this database is continuously updated.

However, I can tell you that as of my last training data:

- ClinVar contained **several hundred thousand** submissions of pathogenic and likely pathogenic variants combined
- The number has been growing steadily, with tens of thousands of new submissions added each year
- The exact count changes frequently as new variants are submitted and existing classifications are updated

For the most current statistics, you would need to check:
1. The ClinVar website directly (www.ncbi.nlm.nih.gov/clinvar/)
2. Their statistics page, which provides up-to-date counts of variants by classification category

The database tracks variants across multiple clinical significance categories including: pathogenic, likely pathogenic, uncertain significance, likely benign, and benign, among others.",,6.467477083206177,49,198,True,True,0.5,"Excellent! Based on the ClinVar RDF database query, here's what I found:

## Pathogenic Variants in ClinVar

According to the latest data (Release 2025.01), ClinVar contains:

- **200,004** variants classified as **""Pathogenic""**
- **107,204** variants classified as **""Likely pathogenic""**
- **34,673** variants classified as **""Pathogenic/Likely pathogenic""**

This gives us a total of approximately **341,881 pathogenic or likely pathogenic variants** when including all pathogenic classifications.

### Context
For comparison, ClinVar also contains:
- **1,821,577** variants of uncertain significance (the largest category)
- **993,150** likely benign variants
- **213,802** benign variants
- **145,497** variants with conflicting classifications of pathogenicity

The database contains over **3.5 million total variant records** with clinical interpretations, making it one of the most comprehensive resources for understanding the clinical significance of genetic variants.",,30.692376852035522,22,771,11423,126627,"mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""clinvar""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX cvo: <http://purl.jp/bio/10/clinvar/>\n\nSELECT (COUNT(DISTINCT ?variant) as ?count)\nFROM <http://rdfportal.org/dataset/clinvar>\nWHERE {\n  ?variant a cvo:VariationArchiveType ;\n           cvo:classified_record ?classrec .\n  ?classrec cvo:classifications/cvo:germline_classification/cvo:description ?significance .\n  FILTER(CONTAINS(LCASE(?significance), \""pathogenic\""))\n}""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX cvo: <http://purl.jp/bio/10/clinvar/>\n\nSELECT ?significance (COUNT(?variant) as ?count)\nFROM <http://rdfportal.org/dataset/clinvar>\nWHERE {\n  ?variant a cvo:VariationArchiveType ;\n           cvo:classified_record ?classrec .\n  ?classrec cvo:classifications/cvo:germline_classification/cvo:description ?significance .\n}\nGROUP BY ?significance\nORDER BY DESC(?count)\nLIMIT 20""}}]",CRITICAL,"200,004 pathogenic variants (approximately 6% of all variants)","COMPLEX QUERY requiring classification navigation.

Databases/Resources: ClinVar

Knowledge Required:
- Property path for classification: cvo:classified_record/cvo:classifications/cvo:germline_classification/cvo:description
- Filter for 'Pathogenic' significance
- record_status 'current' filter
- COUNT aggregation pattern

Without proper knowledge: Cannot navigate nested classification structure.

Verified in clinvar_exploration.md Pattern 5 (Clinical Significance Distribution)."
42,2026-01-31,Completeness,How many intractable diseases are registered in the Japanese NANDO ontology?,True,False,True,0.6666666666666666,"I don't have specific information about the exact number of intractable diseases currently registered in the Japanese NANDO (Nanbyo Disease Ontology) with certainty.

NANDO is a disease ontology developed to represent the intractable/rare diseases designated by the Japanese government's intractable disease program. The number of designated intractable diseases in Japan has grown over time - the program originally started with a smaller number of diseases and has expanded significantly over the years to include several hundred diseases.

As of my last training data, Japan's intractable disease program covered over 300 designated intractable diseases, and NANDO would be designed to represent these. However, I cannot provide you with the current exact count in the NANDO ontology without access to the most recent version of the database or ontology documentation.

For the most accurate and up-to-date number, I would recommend checking the official NANDO resources or the Japanese Ministry of Health, Labour and Welfare's information on designated intractable diseases.",,5.785904884338379,54,222,True,True,0.8333333333333334,"Perfect! I found the information about NANDO. According to the MIE file I retrieved, **NANDO (Nanbyo Data) contains 2,777 disease classes** registered as Japanese intractable (rare) diseases.

Here are some key details about NANDO:

- **Total number of diseases: 2,777**
- **Designated diseases with notification numbers: 2,454** (approximately 88% of all diseases)
- **Coverage**: These are intractable diseases maintained by the Japanese government, primarily focusing on designated intractable diseases eligible for government support
- **Multilingual support**: Each disease includes labels in English, Japanese kanji, and hiragana
- **International mapping**: About 2,341 diseases (84%) have mappings to the MONDO Disease Ontology
- **External references**: The ontology includes links to KEGG Disease database, Japanese government documents, and patient information resources

NANDO is organized as a hierarchical taxonomy and is designed to support Japanese healthcare policy, research coordination, and patient information systems. The ontology is maintained quarterly and is licensed under CC BY 4.0.",,28.795909881591797,16,579,42602,133094,"mcp__ols__searchClasses, mcp__ols__listOntologies, mcp__togomcp__get_MIE_file","[{""name"": ""mcp__ols__searchClasses"", ""input"": {""ontologyId"": ""nando"", ""query"": ""*"", ""pageSize"": 1}}, {""name"": ""mcp__ols__listOntologies"", ""input"": {""lang"": ""en""}}, {""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""nando""}}]",CRITICAL,"2,777 disease classes covering designated intractable diseases","COMPLEX QUERY requiring NANDO structure knowledge.

Databases/Resources: NANDO

Knowledge Required:
- GRAPH clause for NANDO on primary endpoint
- Disease class counting pattern
- Understanding of hierarchical taxonomy structure

Without proper knowledge: Cannot identify correct graph or entity types.

Verified in nando_exploration.md Database Overview."
43,2026-01-31,Specificity,Which genes on chromosome 17 have pathogenic variants associated with cancer?,True,True,True,1.0,"Based on my training knowledge, several important genes on chromosome 17 have pathogenic variants associated with cancer:

## Major Cancer Genes on Chromosome 17:

**TP53 (17p13.1)**
- One of the most commonly mutated genes in human cancers
- Germline mutations cause Li-Fraumeni syndrome (increased risk of multiple cancer types)
- Somatic mutations found in ~50% of all cancers

**BRCA1 (17q21.31)**
- Hereditary breast and ovarian cancer syndrome
- Germline pathogenic variants significantly increase lifetime risk of breast (up to 70%) and ovarian cancer (up to 40%)
- Also associated with increased risk of pancreatic and prostate cancers

**ERBB2/HER2 (17q12)**
- Amplification and overexpression in breast cancer (~20% of cases)
- Also involved in gastric and other cancers
- Important therapeutic target

**NF1 (17q11.2)**
- Neurofibromatosis type 1
- Tumor suppressor gene; mutations increase risk of various tumor types including neurofibromas, optic gliomas, and malignant peripheral nerve sheath tumors

**STAT3 (17q21.2)**
- Implicated in various cancers through activation mutations or overexpression

**FLCN (17p11.2)**
- Birt-Hogg-Dubé syndrome
- Associated with increased risk of renal cell carcinoma and other tumors

These are among the most clinically significant, with TP53 and BRCA1 being particularly important in cancer genetics and genetic counseling.",,8.168612957000732,52,390,True,True,1.0,"Based on my search of biological databases, here are the major genes on **chromosome 17** with pathogenic variants associated with cancer:

## Key Cancer-Associated Genes on Chromosome 17

### 1. **BRCA1** (17q21.31)
- **Function**: DNA repair, tumor suppressor
- **Cancer Association**: Responsible for ~40% of inherited breast cancers and >80% of inherited breast and ovarian cancers
- **Gene ID**: 672

### 2. **TP53** (17p13.1)
- **Function**: Tumor suppressor, transcriptional regulation, cell cycle control
- **Cancer Association**: Mutations associated with diverse cancers including Li-Fraumeni syndrome (hereditary cancer syndrome)
- **Gene ID**: 7157

### 3. **ERBB2/HER2** (17q12)
- **Function**: Receptor tyrosine kinase, cell growth signaling
- **Cancer Association**: Amplified/overexpressed in breast, ovarian, and other cancers
- **Gene ID**: 2064

### 4. **NF1** (17q11.2)
- **Function**: Negative regulator of RAS signaling, tumor suppressor
- **Cancer Association**: Neurofibromatosis type 1, juvenile myelomonocytic leukemia
- **Gene ID**: 4763

### 5. **BRIP1/FANCJ** (17q23.2)
- **Function**: DNA helicase, interacts with BRCA1, DNA repair
- **Cancer Association**: Target of germline cancer-inducing mutations, Fanconi anemia
- **Gene ID**: 83990

### 6. **RARA** (17q21.2)
- **Function**: Retinoic acid receptor, transcriptional regulation
- **Cancer Association**: Translocations associated with acute promyelocytic leukemia
- **Gene ID**: 5914

### 7. **FLCN** (17p11.2)
- **Function**: Tumor suppressor
- **Cancer Association**: Birt-Hogg-Dubé syndrome (renal tumors, lung cysts)
- **Gene ID**: 201163

### 8. **MAP2K4** (17p12)
- **Function**: MAPK signaling pathway
- **Cancer Association**: Role in cell proliferation and differentiation
- **Gene ID**: 6416

### 9. **STAT3** (17q21.2)
- **Function**: Transcription activator, cell growth and apoptosis
- **Cancer Association**: Key role in cellular processes related to cancer development
- **Gene ID**: 6774

The ClinVar database search returned **336 pathogenic variants** on chromosome 17 associated with cancer, with BRCA1 and TP53 being the most clinically significant tumor suppressor genes on this chromosome.",,64.81576776504517,27,2394,24155,235534,"mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary","[{""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""chromosome 17 AND cancer AND pathogenic"", ""max_results"": 100}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""chromosome 17[chr] AND cancer AND human[organism]"", ""max_results"": 50}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""BRCA1 human chromosome 17"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""TP53 human chromosome 17"", ""limit"": 5}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""BRCA1[gene] AND human[organism]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""TP53[gene] AND human[organism]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""NF1[gene] AND human[organism]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""gene"", ""ids"": [""672"", ""7157"", ""4763""]}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""ERBB2[gene] AND human[organism]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""RARA[gene] AND human[organism]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""BRIP1[gene] AND human[organism]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""gene"", ""ids"": [""2064"", ""5914"", ""83990""]}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""FLCN[gene] AND human[organism]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""PMP22[gene] AND human[organism]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""gene"", ""ids"": [""201163""]}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""MAP2K4[gene] AND human[organism]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""STAT3[gene] AND human[organism]"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""gene"", ""ids"": [""6416"", ""6774""]}}]",VALUABLE,"Cancer genes on chromosome 17 with pathogenic variants, including BRCA1 (17q21.31), TP53 (17p13.1)","COMPLEX QUERY requiring chromosomal location knowledge.

Databases/Resources: ClinVar

Knowledge Required:
- cytogenetic_location property for chromosomal position
- REGEX filter for chromosome 17 ('^17[pq]')
- Clinical significance filtering for pathogenic
- Gene entity structure

Without proper knowledge: Cannot filter by chromosomal location correctly.

Verified in clinvar_exploration.md Pattern 8 (Gene Location Queries)."
44,2026-01-31,Specificity,What is the GO identifier for the biological process 'autophagy'?,True,True,True,1.0,"The GO identifier for the biological process 'autophagy' is **GO:0006914**.

This term represents the cellular process by which cells degrade and recycle their own cytoplasmic components through the lysosomal (or vacuolar) machinery.",,2.8709299564361572,53,60,True,True,1.0,"The GO identifier for the biological process 'autophagy' is **GO:0006914**.

This is the primary Gene Ontology term for autophagy as a biological process.",,10.367378950119019,9,131,27534,26020,mcp__ols__search,"[{""name"": ""mcp__ols__search"", ""input"": {""query"": ""autophagy""}}]",VALUABLE,GO:0006914,"SIMPLE QUERY - Straightforward ontology term lookup.

Method: OLS4 searchClasses for 'autophagy' in GO

Demonstrates when basic ontology search tools suffice.

Verified in go_exploration.md simple queries section."
45,2026-01-31,Currency,What refinement software is most commonly used for determining protein structures?,True,True,False,0.4,"The most commonly used refinement software for protein structure determination is **PHENIX** (Python-based Hierarchical ENvironment for Integrated Xtallography), particularly its **phenix.refine** module.

Other widely used refinement programs include:

1. **REFMAC5** - Part of the CCP4 suite, very popular especially in the crystallographic community

2. **BUSTER** - A commercial refinement program known for handling difficult cases

3. **CNS** (Crystallography & NMR System) - Historically important, though less commonly used now for routine refinement

4. **Coot** - While primarily a model-building program, it includes some refinement capabilities

The choice often depends on:
- **Method of structure determination** (X-ray crystallography, cryo-EM, NMR)
- **User preference and familiarity**
- **Specific features needed** (e.g., handling of special cases, twinning, etc.)

For **cryo-EM structures**, PHENIX has become particularly dominant, while for **X-ray crystallography**, both PHENIX and REFMAC5 are extremely common. These programs use maximum likelihood methods and can incorporate geometric restraints to produce accurate, well-validated protein structures.",,8.62437391281128,50,290,True,False,0.4,"Based on the biomedical literature from PubMed, the most commonly used refinement software for determining protein structures includes:

## Primary Refinement Software:

1. **REFMAC5** (from the CCP4 package)
   - Widely used for both X-ray crystallography and cryo-EM structure refinement
   - Mentioned extensively in multiple studies including [Servalcat](https://doi.org/10.1107/S2059798321009475) and [LORESTR pipeline](https://doi.org/10.1107/S2059798316014534)
   - Can use external restraints from programs like ProSMART for low-resolution refinement

2. **Phenix** (including Phenix.refine)
   - Comprehensive software package for macromolecular structure determination
   - Handles X-ray, neutron, and electron diffraction data as well as cryo-EM
   - Emphasizes automation and best practices ([DOI](https://doi.org/10.1107/S2059798319011471))
   - Widely cited as a standard refinement pipeline

3. **Buster**
   - Mentioned alongside Phenix and Refmac as a standard refinement tool
   - Commonly used for protein structure refinement in crystallography

## Supporting Software:

- **Coot** - Manual model building and modification software that works with refinement programs
- **iMosflm/MOSFLM** - For data integration and processing of X-ray diffraction images ([DOI](https://doi.org/10.1038/nprot.2017.037))
- **qFit** - For automated multiconformer model building ([DOI](https://doi.org/10.1101/2023.06.28.546963))
- **Servalcat** - New tool that facilitates refinement using REFMAC5 for cryo-EM structures

The choice between these programs often depends on the experimental method (X-ray crystallography vs. cryo-EM), resolution of the data, and specific features needed. **Phenix and REFMAC5 are consistently mentioned as the most widely adopted refinement platforms** in structural biology.

According to PubMed, these tools continue to evolve with improvements for handling high-resolution cryo-EM data and low-resolution crystallographic data.",,29.11107087135315,15,857,10506,80273,"mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata","[{""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""protein structure refinement software crystallography"", ""max_results"": 30}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""macromolecular refinement programs X-ray crystallography"", ""max_results"": 30}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""37425870"", ""36358983"", ""34605431"", ""32418327"", ""31588918"", ""30596142"", ""28569763"", ""27710936""]}}]",VALUABLE,"PHENIX (71,337 structures), REFMAC (70,213 structures), CNS (22,819 structures)","COMPLEX QUERY requiring software category knowledge.

Databases/Resources: PDB

Knowledge Required:
- Software category traversal (has_softwareCategory/has_software)
- Classification filter for 'refinement'
- GROUP BY for aggregation
- FROM graph clause

Without proper knowledge: Cannot navigate software category structure.

Verified in pdb_exploration.md Pattern 5 (Software Usage Statistics)."
46,2026-01-31,Currency,What approved drugs have been indicated for inflammatory diseases?,True,True,False,0.25,"Based on my training knowledge, here are major classes of approved drugs indicated for inflammatory diseases:

## Biologics/Monoclonal Antibodies

**TNF-α Inhibitors:**
- Infliximab (Remicade)
- Adalimumab (Humira)
- Etanercept (Enbrel)
- Golimumab (Simponi)
- Certolizumab pegol (Cimzia)

**IL-6 Inhibitors:**
- Tocilizumab (Actemra)
- Sarilumab (Kevzara)

**IL-17 Inhibitors:**
- Secukinumab (Cosentyx)
- Ixekizumab (Taltz)

**IL-12/23 Inhibitors:**
- Ustekinumab (Stelara)

**IL-23 Inhibitors:**
- Guselkumab (Tremfya)
- Risankizumab (Skyrizi)

**B-cell Depleting:**
- Rituximab (Rituxan)

**T-cell Costimulation Blocker:**
- Abatacept (Orencia)

## Small Molecule Drugs

**JAK Inhibitors:**
- Tofacitinib (Xeljanz)
- Baricitinib (Olumiant)
- Upadacitinib (Rinvoq)

**DMARDs (Disease-Modifying Anti-Rheumatic Drugs):**
- Methotrexate
- Sulfasalazine
- Leflunomide
- Hydroxychloroquine

## Corticosteroids
- Prednisone
- Methylprednisolone
- Dexamethasone

## NSAIDs
- Ibuprofen
- Naproxen
- Celecoxib
- Indomethacin

These drugs are used for conditions like rheumatoid arthritis, psoriasis, inflammatory bowel disease, ankylosing spondylitis, and other inflammatory conditions.",,8.182219982147217,47,510,True,True,0.8333333333333334,"Based on my search of biomedical databases, here are **approved drugs indicated for inflammatory diseases**:

## Biologic DMARDs (Disease-Modifying Anti-Rheumatic Drugs)

### TNF-α Inhibitors
1. **Infliximab** (CHEMBL1201581) - Monoclonal antibody targeting TNF-α
2. **Adalimumab** (CHEMBL1201580) - Monoclonal antibody targeting TNF-α
3. **Etanercept** (CHEMBL1201572) - TNF receptor fusion protein

### Interleukin Inhibitors
4. **Tocilizumab** (CHEMBL1237022) - IL-6 receptor antagonist
5. **Ustekinumab** (CHEMBL1201835) - IL-12/IL-23 inhibitor
6. **Secukinumab** (CHEMBL1743068) - IL-17A inhibitor

## Small Molecule Anti-Inflammatory Drugs

7. **Methotrexate** (CHEMBL3244648) - Traditional DMARD
8. **Prednisone** (CHEMBL635) - Corticosteroid
9. **Colchicine** (CHEMBL107) - Anti-inflammatory (gout, familial Mediterranean fever)
10. **Tofacitinib** (CHEMBL2103743, CHEMBL221959) - JAK inhibitor

## Additional Emerging Therapies

According to PubMed, recent research has identified several other therapeutic classes for inflammatory diseases:

- **Mirikizumab** (CHEMBL3990014) - IL-23p19 inhibitor for inflammatory bowel disease
- **Brazikumab** (CHEMBL3833372) - Anti-inflammatory biologic
- **Ropsacitinib** (CHEMBL4459585) - JAK inhibitor

According to articles retrieved from PubMed, Matrix metalloproteinase-9 (MMP-9) modulation has become an important therapeutic target, with several approved drugs showing anti-inflammatory effects through MMP-9 modulation, including statins, ACE inhibitors, ARBs, metformin, and sub-antimicrobial dose doxycycline ([DOI](https://doi.org/10.3390/pharmaceutics17111425)).

Research also shows that kinase inhibitors are emerging as transformative agents in allergic and inflammatory diseases, with Bruton's tyrosine kinase (BTK) inhibitors approved for chronic urticaria and JAK inhibitors showing efficacy in atopic dermatitis ([DOI](https://doi.org/10.1016/j.jaip.2025.10.047)).

These drugs are used to treat various inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune and inflammatory disorders.",,60.01144099235535,31,1783,8788,146662,"mcp__chembl__search_chembl_molecule, mcp__pubmed__search_articles, mcp__togomcp__search_chembl_molecule, mcp__pubmed__get_article_metadata, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule","[{""name"": ""mcp__chembl__search_chembl_molecule"", ""input"": {""query"": ""inflammatory disease approved drug"", ""limit"": ""20""}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""approved drugs inflammatory diseases indication"", ""max_results"": 20}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""inflammatory disease"", ""limit"": 20}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41614081"", ""41487823"", ""41533826"", ""41304763"", ""41285205""]}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""infliximab"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""adalimumab"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""etanercept"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""methotrexate"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""prednisone"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""tocilizumab"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""ustekinumab"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""colchicine"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""secukinumab"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""tofacitinib"", ""limit"": 5}}]",CRITICAL,"List of drugs with inflammatory disease indications from ChEMBL, including various anti-inflammatory agents","COMPLEX QUERY requiring DrugIndication knowledge.

Databases/Resources: ChEMBL

Knowledge Required:
- DrugIndication entity with hasMeshHeading
- highestDevelopmentPhase filtering
- CONTAINS for disease keyword matching
- hasMesh for MeSH term integration

Without proper knowledge: Cannot navigate DrugIndication model.

Verified in chembl_exploration.md Pattern 4."
47,2026-01-31,Precision,What is the highest resolution protein structure currently available in the PDB?,True,False,False,0.4444444444444444,"I don't have access to real-time PDB data or know the current state of the database with certainty, as structures are continuously being added and my training data has a cutoff date.

However, I can tell you that historically, the highest resolution protein structures in the PDB have been in the range of **0.48-0.54 Å**. Some notable ultra-high resolution structures include:

- **Crambin** - which has held records with resolutions around 0.48-0.54 Å
- Small, well-ordered proteins that diffract exceptionally well

These ultra-high resolution structures are quite rare and typically require:
- Very small, rigid proteins
- Exceptional crystal quality
- Specialized data collection techniques
- Often cryo-cooling conditions
- Synchrotron radiation sources

For the absolute current record holder, you would need to query the PDB directly or check their statistics pages, as new structures are deposited regularly and methods continue to improve.",,6.776010990142822,51,218,True,False,0.4444444444444444,"Perfect! The highest resolution protein structures currently available in the PDB are at **0.48 Å (angstroms)** resolution. There are two structures that share this record:

1. **5D8V** - Ultra-high resolution structure of high-potential iron-sulfur protein
2. **3NIR** - Crystal structure of small protein crambin at 0.48 Å resolution

Both were determined using X-ray diffraction. This represents truly atomic-level resolution where individual atoms and even electron density details can be clearly resolved.

For context, these are followed by:
- **1EJG** - Crambin at 0.54 Å (also ultra-high resolution)
- **3P4J** - Z-DNA structure at 0.55 Å
- **5NW3** - Perdeuterated Pyrococcus furiosus Rubredoxin at 0.59 Å

It's worth noting that achieving such ultra-high resolution requires exceptional crystal quality, intense X-ray sources (often synchrotron radiation), careful data collection, and favorable protein characteristics (typically small, stable proteins that form highly ordered crystals). These structures provide unprecedented detail about protein structure, including hydrogen atoms and subtle electronic features.",,31.745661973953247,21,917,14168,119411,"mcp__togomcp__search_pdb_entity, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""highest resolution structure"", ""limit"": 20}}, {""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""pdb""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""pdb"", ""sparql_query"": ""PREFIX pdbx: <http://rdf.wwpdb.org/schema/pdbx-v50.owl#>\nPREFIX xsd: <http://www.w3.org/2001/XMLSchema#>\n\nSELECT ?entry_id ?title ?resolution ?method\nFROM <http://rdfportal.org/dataset/pdbj>\nWHERE {\n  ?entry a pdbx:datablock .\n  BIND(STRAFTER(str(?entry), \""http://rdf.wwpdb.org/pdb/\"") AS ?entry_id)\n  ?entry pdbx:has_structCategory/pdbx:has_struct ?struct ;\n         pdbx:has_refineCategory/pdbx:has_refine ?refine ;\n         pdbx:has_exptlCategory/pdbx:has_exptl ?exptl .\n  ?struct pdbx:struct.title ?title .\n  ?refine pdbx:refine.ls_d_res_high ?resolution .\n  ?exptl pdbx:exptl.method ?method .\n  FILTER(xsd:decimal(?resolution) > 0 && xsd:decimal(?resolution) < 1.0)\n}\nORDER BY xsd:decimal(?resolution)\nLIMIT 10""}}]",CRITICAL,Crambin at 0.48 Å resolution (PDB: 3NIR) or HiPIP at 0.48 Å (PDB: 5D8V),"COMPLEX QUERY requiring numeric type conversion.

Databases/Resources: PDB

Knowledge Required:
- xsd:decimal() conversion for resolution comparison
- ORDER BY with numeric conversion for proper ordering
- X-ray diffraction filter (NMR lacks resolution)
- LIMIT for top result

Without proper knowledge: String ordering gives incorrect results.

Verified in pdb_exploration.md Pattern 1 and simple queries section."
48,2026-01-31,Precision,What is the ChEMBL ID for the drug Imatinib?,True,True,True,1.0,"The ChEMBL ID for Imatinib is **CHEMBL941**.

Imatinib (also known by the brand name Gleevec/Glivec) is a tyrosine kinase inhibitor used primarily to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).",,2.776672124862671,55,85,True,True,1.0,"The **ChEMBL ID for Imatinib is CHEMBL941**.

Additionally, the mesylate salt form (Imatinib mesylate, which is the marketed form - brand name Gleevec/Glivec) has the ChEMBL ID **CHEMBL1642**.",,14.803961038589478,9,178,574,52656,mcp__togomcp__search_chembl_molecule,"[{""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""Imatinib"", ""limit"": 5}}]",VALUABLE,CHEMBL941,"SIMPLE QUERY - Straightforward drug lookup.

Method: search_chembl_molecule('imatinib')

Demonstrates when basic ChEMBL search tools suffice.

Verified in chembl_exploration.md simple queries section."
